Dublin, Aug. 16, 2016 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the "Global MRSA Drugs Market 2016-2020" report to their offering.

The report forecasts the global MRSA drugs market to grow at a CAGR of 1.34% during the period 2016-2020.

The report has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Strategic alliances and M&A will be the key trend for market growth. Strategic alliances help co-develop and commercialize drugs. These agreements enable the use of technical expertise from both companies, as well as the use of regulatory and development experience gained by one company for the support of pipeline candidates of another company. They ensure the in-flow of adequate funds from both the companies, reducing liability costs for individual companies in case of failures. M&A are usually intended to increase the market penetration of the acquirer or enhance the product portfolio of the parent company.

According to the report, growing awareness of diseases will be a key driver for market growth because it has increased the use of drugs. October is celebrated as World MRSA Awareness Month. European Antibiotic Awareness Day was celebrated on November 18, 2014 to raise awareness of antibiotic resistance and promote judicious use of antibiotics. The US Department of Health and Human Services developed Healthy People 2020, which aims to prevent and treat infectious diseases. Other awareness programs include World Hand Hygiene Day on May 5, National Infection Control Week in the third week of October, World Pneumonia Day on November 12, and Antibiotic Awareness Week in the third week in November. These programs help increase the treatment seeking population, thus driving the market.

Further, the report states that patent expiries and generic penetration will be the challenges for by the market.

Key vendors

• Allergan
• Merck & Co.
• Pfizer
• Theravance Biopharma

Key Topics Covered:

PART 01: Executive summary

PART 02: Scope of the report

PART 03: Market research methodology

PART 04: Introduction

PART 05: Key buying criteria

PART 06: Antibacterial: Overview

PART 07: Antimicrobial resistance

PART 08: Legislation relating to antibiotics use in US

PART 09: Pipeline analysis

PART 10: Market landscape

PART 11: Market segmentation by drug class

PART 12: Market segmentation by drug origin

PART 13: Market segmentation by MOA

PART 14: Geographical segmentation

PART 15: Market drivers

PART 16: Impact of drivers

PART 17: Market challenges

PART 18: Impact of drivers and challenges

PART 19: Market trends

PART 20: Vendor landscape

For more information about this report visit http://www.researchandmarkets.com/research/trn7zd/global_mrsa_drugs

Related Topics: Infectious Diseases Drugs

CONTACT: Research and Markets
         Laura Wood, Senior Manager
         press@researchandmarkets.com

         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900

         U.S. Fax: 646-607-1907
         Fax (outside U.S.): +353-1-481-1716